194 related articles for article (PubMed ID: 3259154)
1. The safety of administration of massive doses of methotrexate (50 g) with equimolar citrovorum factor rescue in adult patients.
Reggev A; Djerassi I
Cancer; 1988 Jun; 61(12):2423-8. PubMed ID: 3259154
[TBL] [Abstract][Full Text] [Related]
2. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
[TBL] [Abstract][Full Text] [Related]
3. Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole.
Yang CH; Yang LJ; Jaing TH; Chan HL
Int J Dermatol; 2000 Aug; 39(8):621-3. PubMed ID: 10971734
[TBL] [Abstract][Full Text] [Related]
4. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
[TBL] [Abstract][Full Text] [Related]
6. [High-dose methotrexate with citrovorum factor rescue (HD-MTX-CFR) in the treatment of malignant solid tumors--clinical analysis of 62 patients].
Wang QL; Sun Y; Zhou JC; Song SZ; Feng FY; Lu L; Yie ZS
Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):152-4. PubMed ID: 3264785
[TBL] [Abstract][Full Text] [Related]
7. Rescue from high-dose methotrexate with 5-methyltetrahydrofolate.
Reggev A; Djerassi I
Cancer Treat Rep; 1986 Feb; 70(2):251-3. PubMed ID: 3948189
[TBL] [Abstract][Full Text] [Related]
8. [High dose methotrexate with leucovorin rescue in the treatment of malignant lymphoma].
Sampi K; Hattori M
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1068-73. PubMed ID: 6985194
[TBL] [Abstract][Full Text] [Related]
9. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
10. Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
Relling MV; Fairclough D; Ayers D; Crom WR; Rodman JH; Pui CH; Evans WE
J Clin Oncol; 1994 Aug; 12(8):1667-72. PubMed ID: 8040679
[TBL] [Abstract][Full Text] [Related]
11. High-dose leucovorin as sole therapy for methotrexate toxicity.
Flombaum CD; Meyers PA
J Clin Oncol; 1999 May; 17(5):1589-94. PubMed ID: 10334548
[TBL] [Abstract][Full Text] [Related]
12. Daily profiles of plasma phenylalanine and tyrosine in patients with osteogenic sarcoma during treatment with high-dose methotrexate-citrovorum rescue.
Hilton MA; Bertolone S; Patel CC
Med Pediatr Oncol; 1989; 17(4):265-70. PubMed ID: 2787470
[TBL] [Abstract][Full Text] [Related]
13. 5-fluorouracil modulates the toxicity of high dose methotrexate.
White RM
J Clin Pharmacol; 1995 Dec; 35(12):1156-65. PubMed ID: 8750366
[TBL] [Abstract][Full Text] [Related]
14. Ambulatory High-dose Methotrexate Administration in Pediatric Osteosarcoma Patients at a Single Institution in Argentina.
Villegas Rubio JA; Cacciavillano W; Rose A; Zubizarreta P; Scopinaro M
J Pediatr Hematol Oncol; 2017 Oct; 39(7):e349-e352. PubMed ID: 28937522
[TBL] [Abstract][Full Text] [Related]
15. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
[TBL] [Abstract][Full Text] [Related]
16. Phase II and pharmacokinetic study of high-dose methotrexate in the treatment of advanced gynecologic malignancy. A Southwest Oncology Group Trial.
Hilgers RD; Alberts DS; Standefer JC; Skipper BE; Miles NJ; Borst J
Gynecol Oncol; 1984 May; 18(1):62-70. PubMed ID: 6609105
[TBL] [Abstract][Full Text] [Related]
17. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.
Widemann BC; Balis FM; Kim A; Boron M; Jayaprakash N; Shalabi A; O'Brien M; Eby M; Cole DE; Murphy RF; Fox E; Ivy P; Adamson PC
J Clin Oncol; 2010 Sep; 28(25):3979-86. PubMed ID: 20679598
[TBL] [Abstract][Full Text] [Related]
18. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
19. [Therapy of solid tumors using high-dose methotrexate and citrovorum factor].
Baumgartner G; Heinz R; Karrer K; Pridun N; Lutz D
Osterr Z Onkol; 1977; 3(5-6):141-8. PubMed ID: 300863
[TBL] [Abstract][Full Text] [Related]
20. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
